SEARCH

SEARCH BY CITATION

References

  • 1
    Harvey PD, Howanitz E, Parrella M et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites. Am. J. Psychiatry 1998; 155: 10801086.
  • 2
    Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 1996; 153: 321330.
  • 3
    Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005; 162: 495506.
  • 4
    Keefe RS, Sweeney JA, Gu H et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. Am. J. Psychiatry 2007; 164: 10611071.
  • 5
    Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 2001; 158: 176184.
  • 6
    McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry 2007; 164: 17911802.
  • 7
    Liberman RP, Gutkind D, Mintz J et al. Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. Compr. Psychiatry 2002; 43: 469473.
  • 8
    Wykes T, Reeder C, Corner J, Williams C, Everitt B. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr. Bull. 1999; 25: 291307.
  • 9
    Nelson HE, O'Connell A. Dementia: The estimation of premorbid intelligence levels using the new adult reading test. Cortex 1978; 14: 234244.
  • 10
    Matsuoka K, Uno M, Kasai K, Koyama K, Kim Y. Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin. Neurosci. 2006; 60: 332339.
  • 11
    Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004; 68: 283297.
  • 12
    Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: Validation of the Japanese version. Psychiatry Clin. Neurosci. 2007; 61: 602609.
  • 13
    Iwasaki S, Miyauchi M, Oshima I et al. The development of Life Assessment Scale for the Mentally Ill: An assessment of the reliability. Seishin Igaku 1994; 36: 11391151 (in Japanese).
  • 14
    Nemoto T, Kashima H, Mizuno M. Contribution of divergent thinking to community functioning in schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2007; 31: 517524.
  • 15
    Ikebuchi E, Suzuki H, Ando N et al. Effects of atypical antipsychotics in a program improving insight into schizophrenia. Seishin Igaku 2007; 49: 607617 (in Japanese).
  • 16
    Guo X, Zhai J, Wei Q et al. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study. Neurosci. Lett. 2011; 503: 141146.
  • 17
    Riedel M, Schennach-Wolff R, Musil R et al. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum. Psychopharmacol. 2010; 25: 116125.
  • 18
    Lindenmayer JP, MuGurk SR, Mueser KT et al. A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatry Serv. 2008; 59: 241247.
  • 19
    Lawler CP, Prioleau C, Lewis MM et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612627.
  • 20
    Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003; 60: 681690.
  • 21
    Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005; 8: 457472.
  • 22
    Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: A randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am. J. Psychiatry 2006; 163: 19181925.
  • 23
    Bilder RM, Goldman RS, Volavka J et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2002; 159: 10181028.